Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.44, moving -1.99% from the previous trading session. This change lagged the S&P 500's 0.21% loss on the day. Meanwhile, the ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

Factorial, a Spanish startup supplying human resources software to enterprises, is in early discussions to raise new funding that will double its valuation to $2 billion, according to people familiar ...

Strategic collaboration explores manufacturing infrastructure for Solstice™, a high energy density, solid-state platform designed for extended range and high temperature stability BOSTON & SEOUL, ...

The co-founders of startup Ricursive Intelligence seemed destined to be co-founders. Anna Goldie, CEO, and Azalia Mirhoseini, CTO, are so well-known in the AI community that they were among those AI ...

Boston-based Factorial has landed the strategic partnership and investments it said is needed to bring a high-performing electric vehicle battery to market by 2027. Late last year, the company ...

Karma Automotive and Massachusetts-based battery developer Factorial Energy have announced the companies are working together to bring a solid-state battery program to a production vehicle in the ...

Factorial has rolled out a striking out-of-home activation in Paris, transforming the promise of AI-powered efficiency into a tangible, real-world experience. Conceptualised by creative agency ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

The solid-state battery race is heating up. Factorial Energy, a Massachusetts-based start-up, plans to go public in mid-2026. The listing will provide $100 million in capital to advance its battery ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...